WO2005123762B1 - Codon-optimized HPV16 li for salmonella vaccine strains against human papillomavirus type 16 - Google Patents

Codon-optimized HPV16 li for salmonella vaccine strains against human papillomavirus type 16

Info

Publication number
WO2005123762B1
WO2005123762B1 PCT/IB2005/001725 IB2005001725W WO2005123762B1 WO 2005123762 B1 WO2005123762 B1 WO 2005123762B1 IB 2005001725 W IB2005001725 W IB 2005001725W WO 2005123762 B1 WO2005123762 B1 WO 2005123762B1
Authority
WO
WIPO (PCT)
Prior art keywords
hpv
prokaryotic microorganism
salmonella enterica
recombinant
salmonella
Prior art date
Application number
PCT/IB2005/001725
Other languages
French (fr)
Other versions
WO2005123762A3 (en
WO2005123762A2 (en
Inventor
Denise Nardelli
Original Assignee
Indian Immunologicals Ltd
Denise Nardelli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Indian Immunologicals Ltd, Denise Nardelli filed Critical Indian Immunologicals Ltd
Priority to CN2005800278872A priority Critical patent/CN101115766B/en
Priority to JP2007516066A priority patent/JP4769247B2/en
Publication of WO2005123762A2 publication Critical patent/WO2005123762A2/en
Publication of WO2005123762A3 publication Critical patent/WO2005123762A3/en
Publication of WO2005123762B1 publication Critical patent/WO2005123762B1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/542—Mucosal route oral/gastrointestinal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20023—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

The present invention relates to a novel nucleic acid sequence (HPV16 L1S) encoding antigenic HPV16 L1 protein as provided in SEQ ID NO: 1, wherein the said sequence has atleast one modified codon for optimum stability of recombinant plasmid vector when transformed in the prokaryotic micro-organism for improved immunogenicity of the resulting prokaryotic micro-organism. The invention further relates to constructing recombinant vectors pFS14nsdHPV16L1 and pFS14nsdHPV16 kan L1S harboring SEQ ID NO: 1, wherein the former carries Ampicillin and the latter, Kanamycin as a selection marker. The invention also relates to an attenuated strain of a prokaryotic micro-organism transformed with nucleic acid encoding HPV16 (Human Papillomavirus) major capsid protein and expressing the corresponding protein. In addition the invention discloses a process of producing a vaccine based on prokaryotic micro-organism for the treatment of papillomavirus infection and associated risk of cancer.

Claims

AMENDED CLAIMS+ Statement[received by the International Bureau on 11 April 2006 (11/04/06) . . original claims 1-23 replaced by new claims 1-21 [3 pages)]
1. A novel nucleic acid sequence as shown in SEQ ID NO: 1 encoding antigenic HPV 16 Ll protein and having one or more modified codon compared to the wild- type sequence, wherein said modified sequence stabilizes a recombinant plasmid vector harboring said modified sequence when introduced in a prokaryotic microorganism.
2. A recombinant plasmid vector comprising nucleic acid sequence as claimed in claim 1.
3. A recombinant plasmid vector as claimed in claim 2, wherein said recombinant plasmid vector is selected from a group consisting of pFS14nsd-HPV16Ll S, pFSnsd-HPV16 kan LlS and pFSnsd-kan HinS-HPV16LlS.
4. A prokaryotic microorganism comprising a recombinant plasmid vector as claimed in claim 2.
5. The prokaryotic microorganism as claimed in claim 4, wherein the prokaryotic microorganism is selected from a group consisting of Salmonella sps, Escherichia coli, Shigella, Yyersinia, Lactobacillus, Mycobacteria and Listeria.
6. The prokaryotic micro-organism as claimed in claim 5, wherein said Salmonella sps is selected from a group consisting of Salmonella enterica serover typhi, Salmonella enterica serover typhimurium , Salmonella enterica serover dublin and Salmonella enterica serover enteritltidis.
7. The prokaryotic microorganism as claimed in claim 6, wherein the strain of Salmonella sps is selected from a group consisting of Salmonella enterica serovar Typhimurium PhoPc (CS022), Salmonella enterica serovar Typhimurium PhoP"(CS015), Salmonella enterica serovar Typhimurium χ4989(Δcya Δcrp-cdt andΔaroA (SL7207)), Salmonella enterica serovar Typhi Ty21a, CVD908 htrA, Ty800.
8. A recombinant prokaryotic microorganism comprising codon modified nucleic acid sequence encoding HPV (Human Papillomavirus) major capsid protein and expressing corresponding protein, wherein said modified nucleic acid sequence stabilizes a recombinant plasmid vector harboring said modified nucleic acid sequence when introduced in a prokaryotic microorganism.
9. The recombinant prokaryotic microorganism as claimed in claim 8, wherein said prokaryotic microorganism is attenuated.
10. The recombinant prokaryotic microorganism as claimed in claim 8, wherein the HPV major capsid protein is selected from a group consisting of HPV strains causing anogenital cancer.
11. The recombinant prokaryotic microorganism as claimed in claim 8, wherein the HPV major capsid protein is selected from a group consisting of HPV strains HPV 6, HPV 11, HPV 16, HPV 18, HPV 31 and HPV 45.
12. The recombinant prokaryotic microorganism as claimed in claim 8, wherein said prokaryotic micro-organisms is selected from a group consisting of Salmonella sps, Escherichia coli, Shigella, Yersinia, Lactobacillus, Mycobacteria, and Listeria.
13. The recombinant prokaryotic microorganism as claimed in claim 12, wherein the Salmonella sps is selected from a group consisting of Salmonella enterica serovar Typhimurium PhoP (CS022), Salmonella enterica serovar Typhimurium PhoP"(CS015), Salmonella enterica serovar Typhimurium χ4989(Δcya Δcrp-cdt andΔaroA (SL7207)), and the Salmonella enterica serovar Typhi, Ty21a, CVD908 htrA, Ty800.
14. A method for producing a recombinant microorganism for use as vaccine comprising of: a. synthesizing a novel nucleic acid as shown in SEQ ID NO: 1 encoding antigenic HPVl 6 Ll protein, b. constructing recombinant plasmid vector harboring nucleic acid sequences as shown in SEQ ID No: 1 by replacing the original HPV 16Ll gene in the plasmid vector ρFS14nsdHPV16Ll, pFS14nsdHPV16 kan Ll or pFSnsd-kan HinS-HPV16Ll, and c. introducing the recombinant plasmid vector into a prokaryotic microorganism to obtain a recombinant microorganism.
15. The method as claimed in claim 14, wherein the introduction of the recombinant plasmid vector is carried out by electroporation.
16. The method as claimed in claim 14, wherein the recombinant plasmid is either pFS14nsdHPV16Ll S, pFS14nsdHPV16 kan LlS and pFSnsd-kan HinS- HPVl 6Ll S
17. The method as claimed in claim 14, wherein wherein the prokaryotic microorganism is selected from a group consisting of Salmonella sps, Escherichia coli, Shigella, Yersinia, Lactobacillus, Mycobacteria, and Listeria.
18. The method as claimed in claim 17, wherein, the Salmonella sps is selected from a group consisting of Salmonella enterica serovar Typhimurium PhoP (CS022), Salmonella enterica serovar Typhimurium PhoP"(CS015), Salmonella enterica serovar Typhimurium χ4989(Δcya Δcrp-cdt andΔaroA (SL7207)) and the Salmonella enterica serovar Typhi, Ty21a, CVD908 htrA, Ty800
19. A method of producing a medicament for the prophylactic or therapeutic treatment of papillomavirus infection and associated risk of cancer comprising use of attenuated strain of a prokaryotic microorganism as claimed in any one of the claims 4 to 12.
20. Use of attenuated strain of a prokaryotic microorganism of any one of the claims 4 to 12, in the preparation of a medicament for the prophylactic or therapeutic treatment of papillomavirus infection and associated risk of cancer.
21. A vaccine comprising a recombinant prokaryotic microorganism comprising of codon modified nucleic acid encoding HPV (Human Papillomavirus) major capsid protein and expressing the corresponding protein, wherein said modified sequence stabilizes a recombinant plasmid vector harboring said modified sequence when introduced in a prokaryotic microorganism.
PCT/IB2005/001725 2004-06-18 2005-06-20 Codon-optimized hpv16 li for salmonella vaccine strains against human papillomavirus type 16 WO2005123762A2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
CN2005800278872A CN101115766B (en) 2004-06-18 2005-06-20 Codon-optimized HPV16LI for salmonella vaccine strains against human papillomavirus type 16
JP2007516066A JP4769247B2 (en) 2004-06-18 2005-06-20 Codon optimized HPV16L1 for Salmonella vaccine strain against human papillomavirus type 16

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CH2004000373 2004-06-18
CHPCT/CH2004/000373 2004-06-18

Publications (3)

Publication Number Publication Date
WO2005123762A2 WO2005123762A2 (en) 2005-12-29
WO2005123762A3 WO2005123762A3 (en) 2006-04-27
WO2005123762B1 true WO2005123762B1 (en) 2006-06-08

Family

ID=35510322

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2005/001725 WO2005123762A2 (en) 2004-06-18 2005-06-20 Codon-optimized hpv16 li for salmonella vaccine strains against human papillomavirus type 16

Country Status (3)

Country Link
JP (1) JP4769247B2 (en)
CN (1) CN101115766B (en)
WO (1) WO2005123762A2 (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1887084A1 (en) * 2006-08-10 2008-02-13 International Investment and Patents SA Plasmids with immunological action
CN100532548C (en) * 2007-02-14 2009-08-26 马润林 Method of increasing yield of human papilloma virus L1 albumen pronucleus expression
CN102178944A (en) * 2010-09-17 2011-09-14 大连雅立峰生物制药有限公司 Expression and application of human papilloma viruses type 16 and 18 L1 proteins in inset cells
SG11201508521SA (en) 2013-04-25 2015-11-27 Vaximm Ag Salmonella-based vectors for cancer immunotherapy targeting wilms' tumor gene wt1
EP2801364A1 (en) * 2013-05-07 2014-11-12 Centre Hospitalier Universitaire Vaudois (CHUV) Salmonella strain for use in the treatment and/or prevention of cancer
CN112280792B (en) * 2013-09-29 2022-06-24 上海泽润生物科技有限公司 Human papilloma virus gene, vector, strain and expression method
EA201790365A1 (en) * 2014-09-11 2017-07-31 Кадила Хелзкэр Лимитед HUMAN PAPILLOMA VIRUS ANTIGENES WITH GOOD IMMUNOLOGICAL PROPERTIES AND CONTAINING THEIR VACCINE
RU2628693C1 (en) * 2016-11-10 2017-08-21 федеральное государственное бюджетное учреждение "Федеральный научно-исследовательский центр эпидемиологии и микробиологии имени почетного академика Н.Ф. Гамалеи" Министерства здравоохранения Российской Федерации (ФГБУ "ФНИЦЭМ им. Н.Ф. Гамалеи" Минздрава России) Recombinant l1hpv16 gene, recombinant pqe-l1/16 plasmid, l1hpv16 protein and their application
CN113528544B (en) * 2021-06-02 2022-07-08 郑州大学 Gene for coding soluble HPV23L1 protein and construction and application of recombinant plasmid thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9621091D0 (en) * 1996-10-09 1996-11-27 Fondation Pour Le Perfectionem Attenuated microorganisms strains and their uses
RU2356943C2 (en) * 2003-03-24 2009-05-27 Мерк Энд Ко., Инк. Nucleic acid molecule encoding hpv 31 l1, expression vector, host cell, virus-like particle and method of its obtainment, vaccine, pharmaceutical composition and methods involving them

Also Published As

Publication number Publication date
WO2005123762A3 (en) 2006-04-27
WO2005123762A2 (en) 2005-12-29
JP4769247B2 (en) 2011-09-07
CN101115766A (en) 2008-01-30
JP2008504020A (en) 2008-02-14
CN101115766B (en) 2013-05-08

Similar Documents

Publication Publication Date Title
WO2005123762B1 (en) Codon-optimized HPV16 li for salmonella vaccine strains against human papillomavirus type 16
Galán et al. Cloning and characterization of the asd gene of Salmonella typhimurium: use in stable maintenance of recombinant plasmids in Salmonella vaccine strains
AU2004290032B2 (en) Optimized expression of HPV 58 L1 in yeast
JP4833962B2 (en) Optimized expression of HPV52L1 in yeast
Aires et al. Production of human papillomavirus type 16 L1 virus-like particles by recombinant Lactobacillus casei cells
RU2360001C2 (en) Optimised expression li hpv45 in yeast
JP2005523716A5 (en)
Ribelles et al. Protection against human papillomavirus type 16-induced tumors in mice using non-genetically modified lactic acid bacteria displaying E7 antigen at its surface
JP2008504020A5 (en)
EP2802349A1 (en) Immunogenic hpv l2-containing vlps and related compositions and methods
Motevalli et al. Supercharged green fluorescent protein delivers HPV16E7 DNA and protein into mammalian cells in vitro and in vivo
Mariz et al. Development of an IP-free biotechnology platform for constitutive production of HPV16 L1 capsid protein using the Pichia pastoris PGK1 promoter
CN108315289B (en) Method for improving yield of glycolic acid in escherichia coli
Sadraeian et al. Modification in media composition to obtain secretory production of STxB-based vaccines using Escherichia coli
Kong et al. Enhanced expression of PCV2 capsid protein in Escherichia coli and Lactococcus lactis by codon optimization
CA2730741C (en) Self-replicating vector lacking an antibiotic-resistance gene
CN109706144A (en) A kind of therapeutic HPV nucleic acid vaccine
CN113462710A (en) Random rewriting DNA information storage method
CN112375774A (en) Construction method of engineering strain for recombinant protein expression
CN114457071A (en) RNA type toxin commonly used in archaea and bacteria and related biological material thereof
RU2546240C1 (en) RECOMBINANT STRAIN OF YEAST Hansenula polymorpha - PRODUCER OF MAJOR CAPSID PROTEIN L1 OF HUMAN PAPILLOMAVIRUS OF TYPE 56
WO2024040885A1 (en) Aminoacyl-trna synthase mutant and use thereof
CN108498793B (en) Pseudomonas fragrans DNA vaccine, preparation method and application thereof
CN1769298B (en) Fusion protein with antitumour action and its coding gene and uses
Jahandideh et al. Production of HPV16-L1 through BL21/pET32a expression system

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
B Later publication of amended claims

Effective date: 20060411

DPE1 Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101)
WWE Wipo information: entry into national phase

Ref document number: 12006502512

Country of ref document: PH

WWE Wipo information: entry into national phase

Ref document number: 2007516066

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Ref document number: DE

WWE Wipo information: entry into national phase

Ref document number: 131/CHENP/2007

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 200580027887.2

Country of ref document: CN

122 Ep: pct application non-entry in european phase
DPE1 Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101)